Troluce Capital Advisors LLC Acquires Shares of 32,297 Janux Therapeutics, Inc. (NASDAQ:JANX)

Troluce Capital Advisors LLC purchased a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 32,297 shares of the company's stock, valued at approximately $1,729,000. Janux Therapeutics accounts for about 0.1% of Troluce Capital Advisors LLC's portfolio, making the stock its 20th biggest holding. Troluce Capital Advisors LLC owned about 0.06% of Janux Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tang Capital Management LLC bought a new position in Janux Therapeutics in the fourth quarter valued at approximately $2,677,000. Tema Etfs LLC acquired a new stake in shares of Janux Therapeutics in the 4th quarter valued at approximately $280,000. Stempoint Capital LP grew its holdings in shares of Janux Therapeutics by 195.2% during the 4th quarter. Stempoint Capital LP now owns 145,876 shares of the company's stock valued at $7,810,000 after purchasing an additional 96,461 shares during the last quarter. Shay Capital LLC bought a new stake in shares of Janux Therapeutics during the 4th quarter valued at approximately $375,000. Finally, Sphera Funds Management LTD. acquired a new position in Janux Therapeutics during the 4th quarter worth approximately $3,659,000. Institutional investors and hedge funds own 75.39% of the company's stock.

Insider Activity

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the transaction, the insider now owns 82,139 shares of the company's stock, valued at $2,640,768.85. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ra Capital Management, L.P. purchased 341,742 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were acquired at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the transaction, the director now directly owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. The trade was a 3.67% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 10,001 shares of company stock worth $313,964 over the last 90 days. 29.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have weighed in on JANX shares. Wedbush reaffirmed an "outperform" rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Scotiabank dropped their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $95.25.

Janux Therapeutics Trading Up 2.0%

JANX stock traded up $0.51 during mid-day trading on Friday, reaching $25.72. The company's stock had a trading volume of 718,226 shares, compared to its average volume of 870,578. Janux Therapeutics, Inc. has a 12 month low of $22.48 and a 12 month high of $71.71. The business's 50 day moving average price is $28.14 and its 200 day moving average price is $39.91. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -21.98 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, equities analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.